
Kiniksa Pharmaceuticals Ltd. Class A (($KNSA)) has held its Q3 earnings call. Read on for the main highlights of the call. Kiniksa Pharmaceuticals delivered a strongly positive earnings call, marked
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| KNSA | Kiniksa Pharmaceuticals | 94.23 | 54.79 | 138.91% |
| Name | Price | % Change | |
|---|---|---|---|
| $94.23 | +138.91% |

Kiniksa Pharmaceuticals Ltd. Class A (($KNSA)) has held its Q3 earnings call. Read on for the main highlights of the call. Kiniksa Pharmaceuticals delivered a strongly positive earnings call, marked

JPMorgan raised the firm’s price target on Kiniksa (KNSA) to $122 from $107 and keeps an Overweight rating on the shares. Published first on TheFly – the ultimate source for

Kiniksa Pharmaceuticals Ltd. Class A (KNSA) has disclosed a new risk, in the Manufacturing category. Item 4 on mine safety disclosures is noted for Kiniksa Pharmaceuticals Ltd. Class A but

Goldman Sachs raised the firm’s price target on Kiniksa (KNSA) to $101 from $90 and keeps a Buy rating on the shares. Kiniksa delivered a strong Q3 beat-and-raise, with Arcalyst

Kiniksa (KNSA) is up 20.4%, or $14.90 to $87.88. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended

Kiniksa (KNSA) is up 16.5%, or $12.03 to $85.01. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended

Reports Q3 revenue $285.97M, consensus $260.61M. “Kiniksa (KNSA) continues to build a leading IL-1alpha and IL-1beta inhibition franchise, driven by the commercialization of ARCALYST in recurrent pericarditis. In the third

Kiniksa Pharmaceuticals Ltd. Class A (KNSA) is scheduled to report 3rd quarter earnings on 10/27/2026, before the market opens. Regarding Q3 estimates, Wall Street analysts expect Kiniksa Pharmaceuticals Ltd. Class

Kiniksa Pharmaceuticals ( ($KNSA) ) just unveiled an announcement. On October 17, 2026, Kiniksa Pharmaceuticals appointed long-time executive Ross Moat as President and Chief Operating Officer, effective immediately, with Moat

Goldman Sachs analyst Paul Choi raised the firm’s price target on Kiniksa (KNSA) to $90 from $75 and keeps a Buy rating on the shares. Kiniksa delivered another beat-and-raise quarter,
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Mar 2, 2027TBA | $7.57B | $0.25 | $306.56M | -0.22 | 67.36 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.